ASH 2023 | Clinical outcomes are poor for CLL patients treated with venetoclax post-BTKi exposure
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, introduces a real-world study investigating clinical outcomes for patients with chronic lymphocytic leukemia (CLL) when treated with venetoclax following exposure to BTK inhibitors (BTKi). The findings reveal poor time-to-treatment discontinuation (TTD) and time-to-next treatment or death (TNT-D) outcomes for this patient population, which contrasts with venetoclax outcomes in CLL patients who have not had prior BTKi exposure. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics/Janssen, TG Therapeutics, AstraZeneca, Caribou Biosciences, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Epizyme, ADC Therapeutics, BeiGene, Morphosys, Bristol Myers Squibb, Merck, Abbvie; Research Funding: Pharmacyclics/Janssen, Sunesis Pharmaceuticals, Nurix, AstraZeneca, Fate Therapeutics, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Curis, Inc, Epizyme, CRISPR Therapeutics, Bristol Myers Squibb, Merck, Adaptive Biotechnologies; Speakers Bureau: TG Therapeutics, AstraZeneca, Kite, Bristol Myers Squibb.
